Background: Enrollment in health maintenance organizations (HMOs) has increased rapidly during the past 10 years, reflecting a growing emphasis on health care cost containment. To determine whether there is a difference in the treatment and outcome for female patients with breast cancer enrolled in HMOs versus a fee-for-service setting, we compared the 10-year survival and initial treatment of patients with breast cancer enrolled in both types of plans. Methods: With the use of tumor registries covering the greater San Francisco-Oakland and Seattle-Puget Sound areas, respectively, we obtained information on the treatment and outcome for 13 358 female patients with breast cancer, aged 65 years and older, diagnosed between 1985 and 1992. We linked registry information with Medicare data and data from the two large HMOs included in the study. We compared the survival and treatment differences between HMO and fee-for-service care after adjusting for tumor stage, comorbidity, and sociodemographic characteristics. Results: In San Francisco-Oakland, the 10-year adjusted risk ratio for breast cancer deaths among HMO patients compared with fee-for-service patients was 0.71 (95% confidence interval [CI] = 0.59-0.87) and was comparable for all deaths. In Seattle-Puget Sound, the risk ratio for breast cancer deaths was 1.01 (95% CI = 0.77-1.33) but somewhat lower for all deaths. Women enrolled in HMOs were more likely to receive breast-conserving surgery than women in fee-for-service (odds ratio = 1.55 in San FranciscoOakland; 3.39 in Seattle). HMO enrollees undergoing breast-conserving surgery were also more likely to receive adjuvant radiotherapy (San Francisco-Oakland odds ratio = 2.49; Seattle odds ratio = 4.62). Conclusions: Long-term survival outcomes in the two prepaid group practice HMOs in this study were at least equal to, and possibly better than, outcomes in the fee-for-service system. In addition, the use of recommended therapy for early stage breast cancer was more frequent in the two HMOs. [J Natl Cancer Inst 1997; 89:1683-91]
Breast cancer is the second most common cause of cancer deaths among women in the United States, trailing only lung cancer (1) . More than 180 000 women are newly diagnosed with breast cancer and 46 000 die each year, with about 50% of the new cases and 80% of the deaths occurring in women ages 65 years and older. There is limited information about breast cancer care and survival in Health Maintenance Organizations (HMOs). One study in Orange County, CA, reported poorer survival at 7 years for patients with early stage breast cancer treated in eight unspecified HMO hospitals compared with those treated in 118 community hospitals, but the analysis did not account for potential confounders, such as patients' individual insurance status, socioeconomic characteristics, or comorbidity (2) .
From 1980 through 1996, enrollment in HMOs increased from 4% to 20% of the U.S. population (3) , with more than 11% of Medicare beneficiaries enrolled in HMOs in 1996. While some HMOs have lower costs and inpatient use, but similar health outcomes compared with traditional indemnity fee-forservice (FFS) insurance plans (4) (5) (6) , there is growing concern that the rapid growth of the managed care industry may compromise the quality of care for those with serious illness (7) (8) (9) . Although some believe there is a lack of objective evidence of any overall decline in the quality of care under the new system (10), more information is needed on the process and outcomes of care in managed care settings.
A literature review (5) of managed care plan performance showed that HMOs have lower hospital admissions yet similar physician use compared with FFS plans but offer more preventive services. More important, clinical outcome comparisons were mixed, and most did not adequately adjust for casemix. Investigators from the Medical Outcomes Study (MOS) found similar functional outcomes and 7-year mortality rates for patients with hypertension and diabetes in HMO and FFS settings (11) . In another MOS study, declines in physical health among the elderly were greater in HMOs than in FFS plans (12) . An evaluation of the Medicare HMO program found similar outcomes but lower utilization for HMO compared with FFS enrollees (13, 14) .
The purpose of this study was to determine whether there is a difference in 10-year survival and treatment among women at least 65 years old diagnosed with breast cancer who were enrolled in two large, prepaid-care HMOs and patients in FFS plans living in the same geographic areas. We also investigated the influence of other known prognostic variables on survival including age, race, tumor stage, socioeconomic status (SES), and presence of comorbidity. We compared the use of treatments for early stage breast cancer cases in HMO and FFS settings.
Methods

Data Sources and Sample Selection
Data for breast cancer cases diagnosed from 1985 through 1992 were obtained from two population-based cancer registries, one covering the five-county San Francisco-Oakland greater metropolitan area and the other covering the 13-county Seattle-Puget Sound area. Both registries, which cover at least half of the catchment areas of the two HMOs included in the study, also participate in the National Cancer Institute's (NCI) Surveillance, Epidemiology, and End Results 1 (SEER) Program. The SEER Program consists of a system of 11 populationbased tumor registries covering approximately 14% of the United States (1). Each registry collects and reports information on all new cancer diagnoses, including date of diagnosis, stage at diagnosis, whether the cancer is a single or multiple primary tumor, and the date and cause of death. Stage of disease at initial diagnosis for breast cancer cases is identified using the TNM (tumornode-metastasis) classification system adopted by the American Joint Committee on Cancer (15) . Another prognostic variable collected by SEER, estrogen receptor status, was not included, since this item was not routinely collected until the early 1990s. For all cases, we used information collected by the SEER registries on the type of initial surgery and radiation therapy administered or planned during the 4 months following diagnosis. Vital status follow-up at the time of our study was complete through December 1994.
We used a SEER-Medicare linked database to augment the SEER registry data. The methods used and the results of linking SEER with Medicare data are described elsewhere (16) . More than 94% of all SEER cases aged 65 years and older were successfully linked with Medicare claims data. Because our study required information from the SEER-Medicare linkage, eligible cases for the study were women diagnosed with breast cancer at ages 65 years and older whose SEER record had been previously linked with Medicare files. We included women with breast cancer as either a single primary diagnosis or as the first primary diagnosis (with at least one or more subsequent new primary tumors of any site including breast). Newly diagnosed breast cancer cases diagnosed between 1985 and 1992 in San Francisco-Oakland and Seattle-Puget Sound areas were followed for a maximum of 10 years through December 1994. The median follow-up time was 52 months.
We identified all new breast cancer cases reported to the two SEER registries by the two largest HMO plans in these regions, Kaiser Permanente of Northern California (KPNC) and Group Health Cooperative of Puget Sound (GHC). KPNC, the largest and one of the oldest prepaid group plans, was established in the early 1940s and during 1987 through 1990 covered approximately 2.4 million members in Northern California, of which about half reside in the five counties covered by the SEER registry. GHC was established as the first consumer-controlled health plan in 1947. Unlike KPNC, which contracts with a distinct physician organization (The Permanente Medical Group) to provide services to the plan members, GHC directly employs salaried physicians. GHC covered about 385 000 persons in the Puget Sound area during the study period.
Each HMO submitted patient lists to NCI containing the unique SEER case identification number for any patient diagnosed between 1985 and 1992 as having breast cancer while enrolled in the HMO. Personal identifiers were not required, since SEER cases are tracked by case identification numbers that are not associated with names or social security numbers. More than 91% of these HMO patients were continuously enrolled in their HMO from diagnosis through death or last date of follow-up. All cases were classified according to their enrollment status at the time of diagnosis and initial treatment for breast cancer and remained in the HMO category regardless of disenrollment.
Inpatient Medicare claims data spanning 1984 through 1992 for FFS breast cancer cases diagnosed from 1985 through 1992 were used to identify the presence of comorbid conditions at the time of initial diagnosis. To measure comorbidity, we used a Charlson/Deyo comorbidity index. This index was designed and validated using Medicare inpatient hospital claims containing ICD-9-CM diagnostic codes (17, 18) . The modified Charlson/Deyo Index is not a measure of all comorbid diseases, but rather a risk measure for mortality from other causes than the reference condition in our study, breast cancer. Since Medicare inpatient claims data are incomplete for HMOs paid under capitation, we obtained automated inpatient data directly from KPNC and GHC internal accounting systems.
Internal audits of HMO automated inpatient data show that the accuracy of diagnoses recorded is quite high. Inpatient data covering 1984 through 1992 were linked to individual HMO cases by use of the unique SEER case ID number. The HMO inpatient data contained similar information to the Medicare FFS inpatient claims data, including dates of admission and discharge and up to five ICD-9-CM diagnostic and three surgical procedure codes. We used information from inpatient records from the 2 years before diagnosis to compute all the Charlson/Deyo comorbidity index scores reported in this study.
We obtained group-level income and educational attainment variables by linking the census tract reported to SEER for each case with group variables collected by the U.S. Bureau of the Census during the 1990 decennial census. The variables used were the median household income of the census tract and the proportion of adults with less than a high school education. For approximately 8% of the cases, census tracts were unavailable so ZIP Code level information was used.
We began with a sample of 14 171 female breast cancer cases linked with Medicare claims data who were diagnosed in the two regions between 1985 and 1992. We excluded patients enrolled in any other HMO besides KPNC or GHC (n ‫ס‬ 780), since we lacked information on HMO type and comorbidity status, and another 33 cases with missing group education and income values, leaving a final sample size of 13 358 (7176 in San Francisco-Oakland; 6182 in Seattle).
Statistical Analysis
Frequency distributions of age, race, income, education, tumor stage, and comorbidity were compared with enrollment status separately by region. We used standard categorical chi-squared tests to evaluate statistical differences between HMO and FFS cases in the distributions of each independent variable.
For patients diagnosed from 1985 through 1992 and followed through December 1994, we calculated 10-year Kaplan-Meier survival probabilities for deaths from all causes, testing for differences between HMO and FFS settings within each region. Comparisons were stratified by age and stage, but not both simultaneously. We assessed differences between HMO and FFS Kaplan-Meier survival functions using the logrank test.
The Cox proportional hazards regression model was used to estimate the relative risk of overall and breast cancer-specific mortality in the HMO breast cancer cases compared with those in the Medicare FFS system. The Cox regression models permitted estimation of the effects of HMO enrollment status on mortality risk, after adjustment for other patient characteristics, including age at diagnosis, race, stage at diagnosis, whether the diagnosis was a single or first primary cancer, comorbidity, and area-level educational status. We constructed separate survival models to assess overall and breast cancer-specific mortality. In the latter models, we censored nonbreast cancer deaths. We included only one measure of socioeconomic status (SES) because median income and educational status are highly correlated. We included categoric variables for age, race, education (quartiles), stage at diagnosis, single or first primary cancer, and comorbidity. The use of continuous rather than categoric variables for age and education level did not affect the results.
In the Cox models, we tested for two-way interaction terms between HMO enrollment status and age, stage, comorbidity, and region. We detected only one significant interaction term, enrollment status by region, so we constructed separate survival models for Seattle and San Francisco-Oakland. Standard log-log plots were used to evaluate each covariate with respect to the validity of the proportional hazards assumption. No evidence of substantial departures from this assumption was observed.
We constructed separate logistic regression models to estimate the odds ratios for two different treatments comparing HMO to FFS cases with in situ or stage I or II tumors, controlling for all other independent variables contained in the survival models. In one regression model, we examined the use of breastconserving surgery (BCS) versus mastectomy, and in the second model, the use of adjuvant radiotherapy following surgery among all women undergoing BCS. We defined mastectomy using SEER surgical coding as modified radical mastectomy, simple mastectomy, subcutaneous mastectomy, or radical mastectomy. BCS was defined as any of the following: segmental resection, excisional biopsy, lumpectomy, wedge resection, quadrantectomy, tylectomy, nipple resection, or partial mastectomy. Table 1 shows frequency distributions of selected patient characteristics in each area. A higher percentage of HMO cases are younger than FFS cases at diagnosis. The distribution of race is similar in the HMO and FFS settings in both areas, although in San Francisco-Oakland there is a slightly higher representation of white women in the HMO. In Seattle, the HMO has greater representation in the upper quartiles of income and education than FFS. In San Francisco-Oakland, the HMO is underrepresented in the extreme quartiles of education, and the income distribution is similar.
Results
The distribution of stage at initial diagnosis is much more favorable in the HMO setting. Almost half of the HMO patients are diagnosed with stage I breast cancer compared with 43% and 37% of FFS patients in Seattle and San Francisco-Oakland, respectively. Comorbidity scores are higher for FFS compared with HMO cases in both areas. The use of mastectomy for in situ, stage I and stage II invasive breast cancers is lower in the HMOs, with much larger differences observed in Seattle where just 35% of the eligible HMO cases received a mastectomy. Among women having BCS, adjuvant radiotherapy is much more frequent in both HMOs compared with FFS care. Fig. 1 shows the 10-year, Kaplan-Meier probabilities showing overall survival for invasive breast cancer cases according to age at diagnosis, region, and HMO enrollment. There were 4388 deaths over 10 years (of which 1672 were from breast cancer). Overall survival is significantly higher in HMO than in FFS cases in both regions for all ages combined. Among cases 65-69 years of age, the survival functions are significantly different in San Francisco-Oakland (P<.001) but not in Seattle (P ‫ס‬ .29). In the two older age groups, observed survival in both HMOs is consistently better than in their respective FFS comparison groups, with larger differences in San Francisco-Oakland. Fig. 2 . shows overall Kaplan-Meier survival probabilities according to stage at diagnosis (excluding in situ) combining all age groups. In Seattle, HMO cases have a higher 10-year survival than FFS cases for unknown stage, but HMO and FFS cases have similar survival times in all other stage groups. In San Francisco-Oakland, HMO cases have more favorable 10-year survival times than FFS cases, except for stages III/IV combined. We also compared survival functions between the two HMOs and between the two FFS groups. Survival was similar by stage in the two HMOs, but survival in the Seattle FFS group was better than the San Francisco-Oakland FFS group in some stages. Table 2 shows the results of the multivariate Cox regression model. The mortality risk ratios (RRs) for HMO relative to FFS cases are shown for three separate survival models, in each area, for both overall and cause-specific survival. We first assessed HMO-FFS differences adjusting only for patient demographic variables (age, race, and education), then evaluated the effect of adding tumor characteristics (stage at diagnosis and single versus first primary), and finally of adding the comorbidity index to a model containing all other variables. We report the RRs for the adjustment variables for the final model only.
Even after adjusting for patient age, race, and education, overall and cause-specific survival remained consistently better in the San Francisco-Oakland HMO setting. After adjustment for initial stage at diagnosis, the HMO-FFS differences were reduced, with the RR confidence intervals (CI) in Seattle overlapping unity. A larger effect was observed for breast cancerspecific survival than for all-cause survival when adjusting for stage at diagnosis. In the final models, the addition of comorbidity slightly reduced the HMO-FFS differences in overall survival but had minimal effect on cause-specific survival differences. When all variables are included in the survival models, the 10-year RR for HMO compared with FFS cases in San Francisco-Oakland is 0.70 (95% CI ‫ס‬ 0.62-0.79) for deaths due to all causes and 0.71 (95% CI ‫ס‬ 0.59-0.87) for breast cancer deaths. In Seattle, the RR for HMO versus FFS cases was 0.86 (95% CI ‫ס‬ 0.72-1.03) overall and 1.01 (95% CI ‫ס‬ 0.77-1.33) for breast cancer. Adding treatment variables (type of surgery and use of radiotherapy) to the models shown in Table 2 did not change these results. Table 3 shows the results of logistic regression models used to assess differences in the use of BCS and post-BCS radiotherapy in HMO compared with FFS early stage breast cancer cases, adjusting for the same variables used to adjust survival differences in Table 2 . In Seattle, HMO cases are 3.4 times more likely to receive BCS as opposed to a mastectomy than FFS cases, whereas HMO cases in San Francisco-Oakland were 1.6 times more likely to receive BCS. The odds of receiving post-BCS radiotherapy is 4.6 times higher in HMO than FFS cases in Seattle, but only 2.5 times higher in San Francisco-Oakland HMO compared with FFS cases. Adding clinical characteristics and comorbidity to models including only age, race, and education had little effect on the observed odds ratios for both treatment patterns.
Discussion
In the U.S. health care system, insurance status and the degree of cost-sharing are critical components of access to services and health outcomes (19, 20) . The rapid growth of managed care has raised concerns that financial incentives to contain costs by restricting use of services and controlling access to specialty care may lead to poorer care and outcomes. To help address gaps in the understanding of the relationship between health care systems and outcomes, we examined the association between HMO enrollment and long-term survival and treatment of elderly patients with breast cancer. We found that long-term survival following the diagnosis of breast cancer among elderly patients with breast cancer was clearly better in one HMO and slightly but not statistically significantly greater in another compared with FFS cases. We found that the use of certain recommended treatments for early stage breast cancer were more frequently received by women enrolled in both HMO plans.
Our results are consistent with a study of patients with prostate cancer enrolled in GHC in the early 1980s who exhibited higher survival rates than those treated under FFS care after controlling for stage, socioeconomic status (SES), age, and health status (21) . Another study reported minimal HMO-FFS differences in the management of colorectal cancer (22) . Several investigators have reported greater use of breast, cervical, and colorectal cancer screening examinations among the elderly enrolled in HMOs compared with FFS systems (23, 24) .
Our results vary from a 1994 study that found that 7-year survival was lower for cases with localized or regional disease in HMO hospitals relative to non-HMO hospitals (2). Unlike our study, the Orange County study 1) excluded patients with breast cancer treated outside a hospital setting or diagnosed with metastatic disease, 2) had a larger percentage of patients in the study whose tumor size and lymph node status were unknown (22% versus a maximum of 10% in our study), 3) did not identify the type of HMO plans included in their study, so it is unknown whether specific HMOs in the County were excluded, and 4) did not control survival comparisons between HMO and non-HMO hospitals for individual insurance status or other potentially confounding variables, particularly comorbidity, race, and SES. Clinical and socioeconomic variables are likely to differ by type of HMO and hospital and are strongly related to survival of women with breast cancer (17, 25, 26) .
Randomized trials have shown that the effects of breast cancer screening on long-term mortality are due to stage shifting combined with intrastage survival improvements (27) (28) (29) . The stage at diagnosis was the most important independent predictor of long-term survival in our models, and the patient distribution was clearly shifted to earlier stages among the HMO plans. Furthermore, 10-year, all-cause mortality RRs were more favorable for HMO plans compared with FFS care when stage was not included in the survival models. This indicates that more frequent screening (as reflected by the altered stage distribution) explains part of the survival differences. We also found for HMO patients that tumors in both stage I and II were somewhat smaller. Both the shift to earlier stages and the detection of smaller tumors within a stage have been suggested as causes of the mortality reductions observed in randomized trials of screening (29) . Controlling for the stage at diagnosis does not eliminate, however, the increase in survival due to within-stage shifts toward smaller tumor sizes among HMO patients compared with FFS patients. Lead-time bias (which occurs when a screening test advances the time of diagnosis without changing the time of death) and length bias (which results in the detection of biologically less aggressive tumors, including those that would never have been detected via symptoms) are known to limit interpretation of observational studies of screening (30) and may have contributed to the apparently improved survival among HMO patients. Additional variables not available for our study, such as the proportion of the cells in S phase, or estrogen receptor status, may provide important prognostic information that could partly mitigate this problem in subsequent observational studies. Because HMOs can readily issue reminders directly to women, prepaid group and staff model HMO plans may have an advantage over FFS plans in initiating preventive services (31, 32) . When GHC instituted a breast cancer screening program in the mid-1980s, which used regularly mailed reminders to women, a rapid increase in mammography resulted (33, 34) . A study of Medicare HMO-FFS differences in SEER areas between 1985 and 1989 demonstrated a more favorable stage distribution among women with breast cancer enrolled in HMOs, suggesting that screening was more frequent in the HMOs during that period (35) . Since the early 1990s, however, the use of mammography screening has been similar in KPNC as compared with the Northern California region 2 and in GHC as compared with the Seattle area (36) .
Randomized clinical trials have demonstrated a similar 8-year survival for women with localized breast cancer treated with BCS plus radiotherapy versus a mastectomy (37) . Women receiving BCS plus radiotherapy have lower recurrence rates but similar survival than women receiving BCS alone (38, 39) . On the basis of commonly held assumptions that BCS with adjuvant radiotherapy is associated with a better quality of life and randomized trial evidence of its equivalent efficacy to mastectomy, many medical professionals have recommended that BCS plus radiotherapy represents the best quality of care for early stage breast cancer (40, 41) .
We observed a much higher use of BCS in the HMOs relative to FFS plans, with much larger differences between HMO and FFS care in Seattle compared with San Francisco-Oakland. Among patients receiving BCS, HMO patients were more likely to receive adjuvant radiotherapy, with patients enrolled in GHC having the highest use of BCS plus radiotherapy of all subgroups examined. Both HMOs in our study are integrated delivery systems where referrals to specialists should be easier compared with FFS care. However, for uncertain reasons, physicians in GHC have adopted BCS plus radiotherapy as the standard treatment for in situ and early stage breast cancer more often than FFS or KPNC physicians. This is unlikely to be related to financial incentives for GHC physicians to perform BCS. Preliminary analyses at GHC (S. H. Taplin and W. Barlow) have not found cost differences between patients receiving mastectomy and those receiving BCS plus radiotherapy. However, radiation therapy may be more common at GHC than at KPNC because GHC employees radiation oncologists, whereas KPNC contracts for radiation oncology services with outside providers.
The survival advantage of the HMO patients in our study may partly be explained by the participation of healthier individuals in HMO plans. Two survey studies have found that Medicare HMO enrollees are healthier than the Medicare FFS population, with slightly better overall and functional health status, fewer limitations in daily activities, and fewer serious chronic conditions such as cardiovascular disease (14, 42, 43) . Our study employs an observational study design that makes it difficult to disentangle selection bias from the effects of breast cancer screening and treatment. However, the survival analysis attempts to control for confounding effects of baseline health status by incorporating several key variables associated with both health status and HMO enrollment including age, race, educational status, and comorbidity.
For example, those in lower socioeconomic strata have generally poorer health status and thus higher mortality risk independent of health care delivery system (20, 44) . Therefore, a comparison of socioeconomic status using ecologic variables can provide insight into differences in underlying health status. Most KPNC members and the general population in the Northern California region live in predominantly working class areas, however, KPNC members are somewhat less likely to live in poor areas and areas with low education levels (45) . In our sample, we found that HMO breast cancer cases are underrepresented in the lowest SES quartile, more so in Seattle than in San Francisco-Oakland. We observed that those in the lowest education quartile had a slightly higher risk of death over 10 years relative to the highest quartile, consistent with previous studies (25, 46) . Although group-level indicators have been shown to contribute additional explanatory power for other health outcomes, even in the presence of individual-level SES measures, their use as surrogates for individual measures may underestimate the true effect of SES on survival (45, 47) .
Adjustment for comorbidity did not help to explain differences in mortality between HMO and FFS cases. This may be due in part to limitations of how comorbidity was measured. The original Charlson comorbidity index, developed using medical chart data, was shown to be a useful predictor of 10-year risk of death from comorbid diseases in a test cohort of 685 breast cancer patients (17) . Because approximately 90% of sampled cases in this analysis had a zero comorbidity score, it is possible that reliance on inpatient claims diagnosis codes covering a 2-year period prior to diagnosis may yield poor sensitivity for less severe chronic conditions which are managed on an outpatient basis and are potentially associated with long-term mortality.
HMO cases may have systematically lower comorbidity scores than FFS cases not only because they enroll a healthier population, but because HMOs generally have a lower propensity to hospitalize patients with similar conditions (4) . There may also be incentives in FFS systems that do not exist in prepaid group HMOs to include more diagnostic codes on bills to maximize reimbursements. However, the underestimation of comorbidity within the HMO population introduces a bias against our conclusion, and therefore we are more confident that selection bias cannot completely explain our findings.
Managed care settings differ markedly in history and organization. Long-established, nonprofit staff and prepaid staff and group model HMO plans characterized by integrated hospital/ primary care systems differ in several respects from for-profit, Independent Practice Associations (IPAs) with capitated payment structures and contractual relationships between primary and specialty care providers. Our results, limited to the former HMO type plan, are not generalizable to all current managed care settings because of the rapid changes that are taking place in the health care industry. The fastest growing form of managed care is the IPA, which included 41% of all HMO enrollees in 1996, while group and staff model plans covered 28% of enrollees (3).
Evaluating treatment and outcomes of breast cancer in these two HMO plans contributes important information not previously reported about outcomes in managed care settings. These two HMOs embody core features of traditional managed care, which include an emphasis on creating longstanding relationships between patient and providers, preventive care, the practice of evidence-based medicine, less stringent utilization review with greater physician autonomy, and greater coordination of specialty care (7) . Some of the concern over managed care is targeted at the for-profit IPA and Preferred Provider Organizations that have not been historically associated with these characteristics (8) . Therefore, the net impact of the changing face of managed care on the quality of breast cancer care remains uncertain. Further research is needed to assist consumers, providers, and policymakers in understanding the effects of specific organizational and financing of health care delivery on treatment and outcomes for women with breast cancer.
